Abstract
Immunotoxins (ITs) are complex molecules. To be effective, they must have a number of desirable features relating to the linker, the toxin component, the antibody component, and the target antigen, to name just a few. Other chapters in this volume have discussed linkers and toxins. This chapter will focus on target antigens and their corresponding monoclonal antibodies. Discussion will be limited primarily to ITs, defined as an antibody coupled to a protein toxin (including A chains and hemitoxins), although mention will also be made of antigen-toxin conjugates.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Schneider, C., Sutherland, R., Newman, R., and Greaves, M. (1982) Structural features of the cell surface receptor for transferrin is recognized by the monoclonal antibody OKT9. J. Biol. Chem., 257, 8516–8522.
Omary, M.B., and Trowbridge, I.S. (1981) Biosynthesis of the human transferrin receptor in cultured cells. J. Biol. Chem., 256, 1288–1292.
McClelland, A., Kuhn, L.C., and Ruddle, F.H. (1984) The human transferrin receptor gene: Genomic organization and the complete primary structure of the receptor deduced from a cDNA sequence. Cell, 39, 267–274.
Schneider, C., Owen, M.J., Banville, D., and Williams, J.G. (1984) Primary structure of human transferrin receptor deduced from the mRNA sequence. Nature, 311, 675–678.
Stearne, P.A., Pietersz, G.A., and Goding, J.W. (1985) cDNA cloning of the murine transferrin receptor: Sequence of transmembrane and adjacent region. J. Immunol., 134, 3474–3479.
Larrick, J.W., and Cresswell, P. (1976) Modulation of cell surface iron transferrin receptors by cellular density and state of activation. J. Supramolec. Struct., 11, 579–586.
Sutherland, R., Delia, D., Schneider, C., Newman, R., Kemshead, J., and Greaves, M. (1981) Ubiquitous cell-surface glycoprotein on tumor cells is proliferation-associated receptor for transferrin. Proc. Natl. Adad. Sci. USA, 78, 4515–4519.
Gatter, K., Brown, G., Trowbridge, I.S., Woolston, R., and Mason, D.Y. (1983) Transferrin receptors in human tissues: Their distribution and possible clinical relevance. J. Clin. Pathol., 36, 539–545.
Faulk, W.P., Hsi, B., and Stevens, P.J. (1980) Transferrin and transferrin receptors in carcinoma of the breast. Lancet, (Aug. 23), 390–392.
Shindelman, J.E., Ortmeyer, A.E., and Sussman, H.H. (1981) Demonstration of the transferrin receptor in human breast cancer tissue. Potential marker for identifying dividing cells. Int. J. Cancer, 44, 1301–1310.
Jefferies, W.A., Brandon, M.R., Hunt, S.V., Williams, A.F., Gatter, K.C., and Mason, D.Y. (1984) Transferrin receptor on endothelium of brain capillaries. Nature, 312, 162–163.
Lebman, D., Trucco, M., Bottero, L., Lange, B., Pessano, S., and Rovera, G. (1982) A monoclonal antibody that detects expression of transferrin receptor in human erythroid precursor cells. Blood, 59, 671–678.
Lesley, J., Hyman, R., Schulte, R., and Trotter, J. (1984) Expression of transferrin receptor on human hematopoietic progenitors. Cell Immunol., 83, 14–25.
Jefferies, W.A., Brandon, M.R., Williams, A.F., and Hunt, S.V. (1985) Analysis of lymphopoietic stem cells with a monoclonal antibody to the rat transferrin receptor. Immunology, 54, 333–341.
Octave, J., Schneider, Y., Crichton, R., and Trouet, A. (1981) Transferrin uptake by cultured rat embryo fibroblasts. The influence of temperature and incubation time, sub-cellular distribution and short-term kinetic studies. Eur. J. Biochem., 115, 611–618.
Karin, M., and Mintz, B. (1981) Receptor-mediated endocytosis of transferrin in developmentally totipotent mouse teratocarcinoma stem cells. J. Biol. Chem., 256, 3245–3252.
Dickson, R.B., Hanover, J.A., Willingham, M.C., and Pastan, I. (1983) Prelysosomal divergence of transferrin and epidermal growth factor during receptor-mediated endocytosis. Biochemistry, 22, 5667–5674.
Hopkins, C.R., and Trowbridge, I.S. (1983) Internalization and processing of transferrin and the transferrin receptor in human carcinoma A431 cells. Cell Biol., 97, 508–521.
Willingham, M.C., and Pastan, I. (1985) Ultrastructural immunocytochemical localization of the transferrin receptor using a monoclonal antibody in human KB cells. J. Histochem. Cytochem., 33, 59–64.
Pastan, I., Willingham, M.C., and FitzGerald, D.J. (1986) Immunotoxins. Cell, 47, 641–648.
Trowbridge, I.S., and Domingo, D.L. (1981) Anti-transferrin receptor monoclonal antibody and toxin-antibody conjugates affect growth of human tumor cells. Nature, 294, 171–173.
Lesley, J., Domingo, D.L., Schulte, R., and Trowbridge, I.S. (1984) Effect of an antimurine transferrin receptor-ricin A conjugate on bone marrow stem and progenitor cells treated in vitro. Exp. Cell Res., 150, 400–407.
Ramakrishnan, S., and Houston, L.L. (1984) Inhibition of human acute lymphoblastic leukemia cells by immunotoxins: Potentiation by chloroquine. Science, 223, 58–61.
Ramakrishnan, S., Uckun, F.M., and Houston, L.L. (1985) Anti-T-cell immunotoxins containing pokeweed anti-viral protein: Potential purging agents for human autologous bone marrow transplantation. J. Immunol., 135, 3616–3622.
Bjorn, M.J., Larrick, J., Piatak, M., and Wilson, K.J. (1984) Characterization of translational inhibitors from Phytolacca americana. Amino-terminal sequence determinations and antibody-inhibitor conjugates. Biochim. Biophys. Acta, 790, 154–163.
Bjorn, M.J., Ring, D., and Frankel, A. (1985) Evaluation of monoclonal antibodies for the development of breast cancer immunotoxins. Cancer Res., 45, 1214–11221.
Bjorn, M.J., Groetsema, G., and Scalapino, L. (1986) Antibody-Pseudomonas exotoxin A conjugates cytotoxic to human breast cell lines in vitro. Cancer Res., 46, 3262–3267.
Pirker, R., FitzGerald, D.J., Hamilton, T.C., Ozols, R.F., Willingham, M.C., and Pastan, I. (1985) Anti-transferrin receptor antibody linked to Pseudomonas exotoxin as a model immunotoxin in human ovarian carcinoma cell lines. Cancer Res., 45, 751–757.
FitzGerald, D.J., Willingham, M.C., and Pastan, I. (1986) Antitumor effect of an immunotoxin made with Pseudomonas exotoxin in a nude mouse model of human ovarian cancer. Proc. Natl. Acad. Sci. USA, 83, 6627–6630.
FitzGerald, D.J., Bjorn, M.J., Ferris, R.J., Winkelhake, J.L., Frankel, A.E., Hamilton, T.C., Ozolos, R.F., Willingham, M.C., and Pastan, I. (1987) Anti-tumor activity of an immunotoxin in a nude mouse mode of human ovarian cancer. Cancer Res., 47, 1407–1410.
FitzGerald, D.J., Trowbridge, I.S., Pastan, I., and Willingham, M.C. (1983) Enhancement of toxicity of anti-transferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus. Proc. Natl. Acad. Sci. USA, 80, 4134–4136.
Trowbridge, I.S., and Lopez, F. (1982) Monoclonal antibody to transferrin receptor blocks transferrin binding and inhibits human tumor cell growth in vitro. Proc. Natl. Acad. Sci. USA, 79, 1175–1179.
Taetle, R., Castagnola, J., and Mendelsohn, J. (1986) Mechanisms of growth inhibition by anti-transferrin receptor monoclonal antibodies. Cancer Res., 46, 1759–1763.
Trowbridge, I.S., and Domingo, D.L. (1982) Prospects for the clinical use of cytotoxic monoclonal antibody conjugates in the treatment of cancer. Cancer Surveys, 1, 544–556.
Sauvage, C.A., Mendelsohn, J.C., Lesley, J.F., and Trowbridge, I.S. (1987) Effect of monoclonal antibodies that block transferrin receptor function on the in vivo growth of a syngeneic murine leukemia. Cancer Res., 47, 747–753.
Trowbridge, I.S., Lesley, J., and Schulte, R. (1982) Murine cell surface transferrin receptor: Studies with an anti-receptor monoclonal antibody. J. Cell. Physiol., 112, 403–410.
Lesley, J.F., and Schulte, R.J. (1985) Inhibition of cell growth by monoclonal antitransferrin receptor antibodies. Mol. and Cell. Biol., 5, 1814–1822.
Gilliland, D.G., Steplewski, Z., Collier, R.J., Mitchell, K.F., Chang, T.H., and Koprowski, H. (1980) Antibody-directed cytotoxic agents: Use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc. Natl. Acad. Sci. USA, 77, 4539–4543.
Frankel, A.E., Ring, D.B., Tringale, F., and Hsieh-Ma, S.T. (1985) Tissue distribution of breast cancer-associated antigens defined by monoclonal antibodies. J. Biol. Resp. Modif., 4, 273–286.
Pirker, R., FitzGerald, D.J., Hamilton, T.C., Ozols, R.F., Laird, W., Frankel, A.E., Willingham, M.C., and Pastan, I. (1985) Characterization of immunotoxins active against ovarian cancer cell lines. J. Clin. Invest., 76, 1261–1267.
Krolick, K.A., Yuan, D., and Vitetta, E.S. (1981) Specific killing of a human breast carcinoma cell line by a monoclonal antibody coupled to the A-chain of ricin. Cancer Immunol. Immunother., 12, 39–41.
Canevari, S., Orlandi, R., Riparmonti, M., Tagliabue, E., Aguanno, S., Miotti, S., Menard, S., and Colnaghi, M.I. (1985) Ricin A chain conjugated with monoclonal antibodies selectively killing human carcinoma cells in vitro. J. Natl. Cancer Inst., 75, 831–839.
Monaco, M.E., Mack, J., Dugan, M.D., and Ceriani, R. (1986) An antibody-toxin conjugate directed against a human mammary cancer antigen. Ann. N.Y. Acad. Sci, 4645, 389–399.
Coombes, R.C., Buckman, R., Forrester, J.A., Shepherd, V., O’Hare, M.J., Vincent, M., Powles, T.J., and Neville, A.M. (1986) In vitro and in vivo effects of a monoclonal antibody-toxin conjugate for use in autologous bone marrow transplantation for patients with breast cancer. Cancer Res., 46, 4217–4220.
Casellas, P., Brown, J.P., Gros, O., Hellstrom, I., Jansen, F.K., Poncelet, P., Ronucci, R., Vidal, H., and Hellstrom, K.E. (1982) Human melanoma cells can be killed in vitro by an immunotoxin specific for melanoma-associated antigen p97. Int. J. Cancer, 30, 437–443.
Bumol, T.F., Wang, Q.C., Reisfeld, R.A., and Kaplan, N.O. (1983) Monoclonal antibody and an antibody-toxin conjugate to a cell surface proteoglycan of melanoma cells suppress in vivo tumor growth. Proc. Natl. Acad. Sci. USA, 80, 529–533.
Spitler, L.E., del Rio, M., Khentigan, A., and Scannon, P. (1987) Therapy of patients with malignant melanoma using Xomazyme-mel, a monoclonal antimelanoma antibody-ricin A chain immunotoxin: Results of phase I trial. J. Cell. Biochem., 10B (supplement), 54.
Webb, K.S., Liberman, S.N., Ware, J.L., Walther, P.J. (1986) In vitro synergism between hybrid immunotoxins and chemotherapeutic drugs: Relevance to immunotherapy of prostate carcinoma. Cancer Immuno. Immunother, 21, 100–106.
Merriam, J.C., Lyon, H.S., and Char, D.H. (1984) Toxicity of a monoclonal F’(ab’)2: Ricin A conjugate for retinoblastoma in vitro. Cancer Res., 44, 3178–3183.
Tsukazaki, K., Hayman, E.G., and Ruoslahti, E. (1985) Effects of ricin A chain conjugates of monoclonal antibodies to human a-fetoprotein and placental alkaline phosphatase on antigen-producing cells in culture. Cancer Res., 45, 1834–1838.
Embleton, M.J., Byers, V.S., Lee, H.M., Scannon, P., Blackhall, N.W., and Baldwin, R.W. (1986) Sensitivity and selectivity of ricin toxin A chain-monoclonal antibody 79IT/36 conjugates against human tumor cell lines. Cancer Res., 46, 5524–5528.
Thiesen, H., Juhl, H., and Arndt, R. (1987) Selective killing of human bladder cancer cells by combined treatment with A and B chain ricin antibody conjugates. Cancer Res., 47, 419–423.
Bernhard, M.I., Foon, K.A., Oeltmann, T.N., Key, M.E., Hwang, K.M., Clarke, G.C., Christensen, W.L., Hoyer, L.C., Hanna, M.G., Jr., and Oldham, R.K. (1983) Guinea pig line 10 hepatocarcinoma model: Characterization of monoclonal antibody and in vivo effect of unconjugated antibody and antibody conjugated to diphtheria toxin A chain. Cancer Res., 43, 4420–4428.
Hwang, K.M., Foon, K.A., Cheung, P.H., Pearson, J.W., and Oldham, R.K. (1984) Selective antitumor effect on L10 hepatocarcinoma cells of a potent immunoconjugate composed of the A chain of abrin and a monoclonal antibody to a hepatoma-associated antigen. Cancer Res., 44, 4578–4586.
Levin, L.V., Griffin, T.W., Haynes, L.R., and Sedor, C.J. (1982) Selective cytotoxicity for a colorectal carcinoma cell line by a monoclonal anti-carcinoembryonic antigen coupled to the A chain of ricin. J. Biol. Resp. Modif., 1, 149–162.
Griffin, T.W, Haynes, L.R., and DeMartino, J.A. (1982) Selective cytotoxicity of a ricin A-chain-anti-carcinoembryonic antigen antibody conjugate for a human adenocarcinoma cell line. J. Natl. Can. Inst., 69, 799–805.
Goldenberg, D.M., DeLand, F., and Kim, E. (1978) Use of radio-labeled antibodies to carcinoembryonic antigen for the detection and localization of diverse cancers by external photoscanning. N Engl. J. Med., 258, 1384–1386.
Roth, J.A., Ames, R.S., Byers, V., Lee, H.M., and Scannon, P.J. (1986) Monoclonal antibody 45–2D9 conjugated to the A chain of ricin is specificially toxic to c-Ha-rastransfected NIH 3T3 cells expressing gp74. J. Immunol., 136, 2305–2310.
Krolick, K.A., Villemez, C., Isakson, P., Uhr, J.W., and Vitetta, E.S. (1980) Selective killing of normal or neoplastic B cells by antibodies coupled to the A chain of ricin. Proc. Natl. Acad. Sci. USA, 77, 5419–5423.
Oeltmann, T.N., and Forbes, J.T. (1981) Inhibition of mouse spleen cell function by diphtheria toxin fragment A coupled to anti-mouse Thy-1.2 and by ricin A chain coupled to anti-mouse IgM. Arch. Biochem. Biophys., 209, 362–370.
Raso, V., and Griffin, R. (1981) Hybrid antibodies with dual specificity for the delivery of ricin to immunoglobulin-bearing target cells. Cancer Res., 41, 2073–2078.
Krolock, K.A., Uhr, J.W., Slavin, S., and Vitetta, E.S. (1982) In vivo therapy of a murine B cell tumor (BCL1) using antibody-ricin A chain immunotoxins. J. Exp. Med., 155, 1797–1809.
Krolick, K.A., Uhr, J.W., and Vitetta, E.S. (1982) Selective killing of leukemia cells by antibody-toxin conjugates: Implications for autologous bone marrow transplantation. Nature, 295, 604–605.
Vitetta, E.S., Cushley, W., and Uhr, J.W. (1983) Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells. Proc. Natl. Acad. Sci. USA, 80, 6332–6335.
Muirhead, M., Martin, P.J., Torok-Storb, B., Uhr, J.W., and Vitetta, E.S. (1983) Use of an antibody-ricin A-chain conjugate to delete neoplastic B cells from human bone marrow. Blood, 62, 327–332.
Vitetta, E.S., and Uhr, J.W. (1985) Immunotoxins. Ann. Rev. Immunol., 3, 197–212.
Marks, A., Baumal, R., Lei, M., Ahmad, A., and Liu, E. (1985) Inhibition of protein synthesis by monoclonal anti-idiotypic antibody-ricin A chain conjugates in MOPC315 myeloma cells. Anticancer Res., 5, 431–434.
Lowe, J.A., Ling, N.R., Forrester, J.A., Cumber, A.J., and Ross, W.C.J. (1985) Variants of lymphoid lines produced with ricin A-chain monoclonal antibody conjugates. J. Immunol. Meth., 76, 93–104.
DeShambo, R.M., and Krolick, K.A. (1986) Selective in vitro inhibition of an antibody response to purified acetyl-choline receptor by using anti-idiotypic antibodies coupled to the A chain of ricin. J. Immunol., 137, 3135–3139.
Bregni, M., DeFabritiis, P., Raso, V., Greenberger, J., Lipton, J., Nadler, L., Rothstein, L., Ritz, J., and Bast, R.C., Jr. (1986) Elimination of clonogenic tumor cells from human bone marrow using a combination of monoclonal antibody ricin A chain conjugates. Cancer Res., 46, 1208–1213.
Fulton, R.J., Uhr, J.W., and Vitetta, E.S. (1986) The effect of antibody valency and lysosomotropic amines on the synergy between ricin A chain and ricin B chain-containing immunotoxins. J. Immunol., 136, 3103–3109.
Raso, V., Ritz, J., Basala, M., and Schlossman, S.F. (1982) Monoclonal antibody-ricin A chain conjugate selectively cytotoxic for cells bearing the common acute lymphoblastic leukemia antigen. Cancer Res., 42, 457–464.
Lambert, J.M., Senter, P.D., Yau-Young, A., Blattler, W.A., and Goldmacher, V.S. (1985) Purified immunotoxins that are reactive with human lymphoid cells. Monoclonal antibodies conjugated to the ribosome-inactivating proteins gelonin and the pokeweed antiviral proteins. J. Biol. Chem., 260, 12035–12041.
Uckun, F.M., Ramakrishnan, S., and Houston, L.L. (1985) Immunotoxin-mediated elimination of clonogenic tumor cells in the presence of human bone marrow. J. Immunol., 134, 2010–2016.
Uckun, F.M., Ramakrishnan, S., and Houston, L.L. (1985) Increased efficiency in selective elimination of leukemia cells by a combination of a stable derivative of cyclophosphamide and a human B-cell-specific immunotoxin containing pokeweed antiviral protein. Cancer Res., 45, 69–75.
Wiels, J., Junqua, S., Dujardin, P., Le Pecq, J., and Tursz, T. (1984) Properties of immunotoxins against a glycolipid antigen associated with Burkitt’s lymphoma. Cancer Res., 44, 129–133.
May, R.D., Vitetta, E.S., Moldenhauer, G., and Dorken, B. (1987) Selective killing of normal and neoplastic human B cells with anti-CD19- and anti-CD22-ricin A chain immunotoxins. Cancer Drug Delivery, 3, 261–272.
Rennie, D.P., Wright, J., McGregor, A.M., Weetman, A.P., Hall, R., and Thorpe, P. (1983) An immunotoxin of ricin A chain conjugated to thyroglobulin selectively suppresses the anti-thyroglobulin antoantibody response. The Lancet, December 13, 1338–1340.
Killen, J.A., and Lindstrom, J.M. (1984) Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates. J. Immunol., 133, 2549–2553.
Olsberg, C.A., Mikiten, T.M., and Krolick, K.A. (1985) Selective in vitro inhibition of an antibody response of purified acetylcholine receptor by using antigen-ricin A chain immunotoxin. J. Immunol., 135, 3062–3067.
Volkman, D.J., Ahmad, A., Fauci, A.S., and Neville, D.M., Jr. (1982) Selective abrogation of antigen-specific human B cell responses by antigen-ricin conjugates. J. Exp. Med., 156, 634–639.
Morimoto, C., Masuho, Y., Borel, Y., Steinberg, A.D., and Schlossman, S.F. (1983) Selective inhibition of anti-nucleoside-specific antibody production by nucleoside-ricin A conjugate. J. Immunol., 131, 1762–1764.
Youle, R.J., and Neville, D.M., Jr. (1980) Anti-Thy 1.2 monoclonal antibody linked to ricin is a potent cell-type-specific toxin. Proc. Natl. Acad. Sci. USA, 77, 5483–5486.
Houston, L.L., and Nowinski, R.C. (1981) Cell-specific cytotoxicity expressed by a conjugate of ricin and murine monoclonal antibody directed against Thy 1.1 antigen Cancer Res., 41, 3913–3917.
Vallera, D.A., Youle, R.J., Neville, D.M., Jr., and Kersey, J.H. (1982) Bone marrow transplantation across major histocompatibility barriers. V. Protection of mice from lethal graft-vs.-host disease by pretreatment of donor cells with monoclonal anti-Thy-1.2 coupled to the toxin ricin. J. Exp. Med., 155, 949–954.
Youle, R.J., and Neville, D.M., Jr. (1982) Kinetics of protein synthesis inactivation by ricin-anti-Thy 1.1 monoclonal antibody hybrids. Role of the ricin B subunit demonstrated by reconstitution. J. Biol. Chem., 257, 1598–1601.
Vallera, D.A., Youle, R.J., Neville, D.M., Jr., Soderling, C.B., and Kersey, J.H. (1983) Monoclonal antibody toxin conjugates for experimental graft-versus-host disease prophylaxis. Transplantation, 36, 73–80.
Colombatti, M., Nabholz, M., Gros, O., and Bron, C. (1983) Selective killing of target cells by antibody-ricin A chain or antibody-gelonin hybrid molecules: Comparison of cytotoxic potency and use in immunoselection procedures. J. Immunol., 131, 3091–3095.
Ramakrishnan, S., and Houston, L.L. (1984) Comparison of the selective cytotoxic effects of immunotoxins containing ricin A chain or pokeweed antiviral protein and anti-Thy 1.1 monoclonal antibodies. Cancer Res., 44, 201–208.
Ramakrishnan, S., and Houston, L.L. (1984) Prevention of growth of leukemia cells in mice monoclonal antibodies directed against Thy 1.1 antigen disulfide linked to two ribosomal inhibitors: Pokeweed antiviral protein or ricin A chain. Cancer Res., 44, 1398–1404.
Thorpe, P.E., Brown, A.N., Bremmer, J.A., Jr., Foxwell, B.M., and Stirpe, F. (1985) An immunotoxin composed of monoclonal antibody anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: Potent antitumor effects in vitro and in vivo. J. Natl. Cancer Inst., 75, 151–159.
Blakey, D.C., Wawrzynczak, E.J., Stirpe, F., and Thorpe, P.E. (1987) Antitumor activity of a panel of anti-Thy 1.1 immunotoxins made with different ribosome inactivating proteins. ULCA Symposium on Molecular and Cellular Biology, B. Bonavida and R.J. Collier, eds, in press.
Allison, J.P., McIntyre, B.W., Irvin, J., Bloch, D., and Kitto, B. (1983) Monoclonal antibody to tumor specific epitope of murine lymphoma cells: Use in characterization of antigen and in immunotherapy. Hybridoma and Cellular Immortality, B.H. Tom and J.P. Allison, eds. Plenum Pub. Corp., pp 201–219.
Thorpe, P.E., Mason, D.W., Brown, P.N., Simmonds, S.J., Ross, W.C., Cumber, A.J., and Forrester, J.A. (1982) Selective killing of malignant cells in a leukemic rat bone marrow using an antibody-ricin conjugate. Nature, 297, 594–596.
Vallera, D.A., Ashe, R.C., Zanjani, E.D., Kersey, J.H., LeBien, T.W., Beverley, P.C., Neville, D.M., Jr., and Youle, R.J. (1983) Anti-T-cell reagents for human bone marrow transplantation. Ricin linked to three monoclonal antibodies. Science, 222, 512–515.
Kernan, N.A., Knowles, R.W., Burnes, M.J., Broxmeyer, H.F., Lu, L., Lee, H.M., Kawahata, R.T., Scannon, P.J., and Dupont, B. (1984) Specific inhibition of in vitro lymphocyte transformation by an anti-pan T cell (gp67) ricin A chain immunotoxin. J. Immunol., 133, 137–146.
Stong, R.C., Youle, R.J., and Vallera, D.A. (1984) Elimination of clonogenic T-leukemic cells from human bone marrow using anti-Mr 65,000 protein immunotoxins. Cancer Res., 44, 3000–3006.
Stong, R.C., Uckun, F., Youle, R.J., Kersey, J.H., and Vallera, D.A. (1985) Use of multiple T cell-directed intact ricin immunotoxins for autologous bone marrow transplantation. Blood, 66, 627–635.
Casellas, P., Canat, X., Fauser, A.A., Gros, O., Laurent, G., Poncelet, P., and Jansen, F.K. (1985) Optimal elimination of leukemic T cells from human bone marrow with T101-ricin-A-chain immunotoxin. Blood, 65, 269–297.
Douay, L., Gorin, N.C., Lopez, M., Casellas, P., Liance, M.C., Jansen, F.K., Voisin, G.A., Baillou, C., Laporte, J.P., Najman, A., and Duhamel, G. (1985) Evidence for absence of toxicity of T101 immunotoxin on human hematopoietic progenitor cells prior to bone marrow transplantation. Cancer Res., 45, 438–441.
Leonard, J.E., Wang, Q., Kaplan, N.O., and Royston, I. (1985) Kinetics of protein synthesis inactivation in human T-lymphocytes by selective monoclonal antibody-ricin conjugates. Cancer Res., 45, 5263–5269.
Uckun, F.M., Stong, R.C., Youle, R.J., and Vallera, D.A. (1985) Combined ex vivo treatment with immunotoxins and mafosfamid: A novel immunotherapeutic approach for elimination of neoplastic T cells from autologous marrow grafts. J. Immunol., 134, 3504–3515.
Weil-Hillman, G., Runge, W., Jansen, F.K., and Vallera, D.A. (1985) Cytotoxic effect of anti-Mr 67,000 protein immunotoxins on human tumors in a nude mouse model. Cancer Res., 45, 1328–1336.
Weil-Hillman, G., Uckun, F.M., Manske, J.M., and Vallera, D.A. (1987) Combined immunochemotherapy of human solid tumors in nude mice. Cancer Res., 47, 579–585.
Laurent, G., Kuhlein, E., Cassellas, P., Canat, X., Carayon, P., Poncelet, P., Corell, S., Rigal, F., and Jansen, F.K. (1986) Determination of sensitivity of fresh leukemia cells to immunotoxins. Cancer Res., 46, 2289–2294.
Laurent, G., Pris, J., Farcet, J., Carayon, P., Blythman, H., Casellas, P., Poncelet, P., and Jansen, F.K. (1986) Effects of therapy with T101 ricin A-chain immunotoxin in two leukemia patients. Blood, 67, 1680–1687.
Press, O.W., Vitetta, E.S., Farr, A.G., Hansen, J.A., and Martin, P.J. (1986) Evaluation of ricin A chain immunotoxins directed against human T-cells. Cell Immun., 102, 10–20.
Youle, R.J., Uckun, F.M., Vallera, D.A., and Colombatti, M. (1986) Immunotoxins show rapid entry of diphtheria toxin but not ricin via the T3 antigen. J. Immunol., 136, 93–98.
Martin, P.J., Hansen, J.A., and Vitetta, E.S. (1985) A ricin A chain-containing immunotoxin that kills human T lymphocytes in vitro. Blood, 66, 908–912.
Colombatti, M., Greenfield, L., and Youle, R.J. (1986) Cloned fragments of diphtheria toxin linked to T cell-specific antibody identifies regions of B chain active in cell entry. J. Biol. Chem., 261, 3030–3035.
Seon, B.K. (1984) Specific killing of human T-leukemia cells by immunotoxins prepared with ricin A chain and monoclonal anti-human T-cell leukemia antibodies. Cancer Res., 44, 259–264.
Depper, J.M., Leonard, W.J., Kronke, M., Waldmann, T.A., and Greene, W.C. (1984) Augmented T cell growth factor receptor expression in HTLV-1-infected human leukemic T cells. J. Immunol., 133, 1691–1695.
Uchiyama, T., Broder, S., and Waldmann, T A (1981) A monoclonal antibody (anti-Tac) reactive with activated and functionally mature T cells. J. Immunol., 126, 1393–1397.
FitzGerald, D.J., Waldmann, T.A., Willingham, M.C., and Pastan, I. (1984) Pseudomonas exotoxin-anti-Tac cell specific immunotoxin active against cells expressing the human T cell growth factor receptor. J. Clin. Invest., 74, 966–971.
Kronke, M., Depper, J.M., Leonard, W.J., Vitetta, E.S., Waldmann, T.A., and Greene, W.C. (1985) Adult T cell leukemia: A potential target for ricin-A-chain immunotoxins. Blood, 65, 1416–1421.
Kronke, M., Schlick, E., Waldmann, T.A., Vitetta, E.S., and Greene, W.C. (1986) Selective killing of human T-lymphotropic virus-1 infected leukemic T-cells by monoclonal anti-interleukin 2 receptor antibody-ricin A chain conjugates: Potentiation by ammonium chloride and monensin. Cancer Res., 46, 3295–3298.
Pastan, I., FitzGerald, D., Willingham, M.C., and Waldmann, T. (1986) Use of Pseudomonas toxin and ricin A to construct immunotoxins directed against adult T cell leukemia and ovarian cancer. J. Cell Biochem., 10B (supplement), 54.
Nakahara, K., Kaplan, D., Bjorn, M., and Fathman, C.G. (1985) The effectiveness of anti-Ia-Immunotoxins in the suppression of MLR. Transplantation, 42, 205–211.
Shizuru, J.A., Ramakrishnan, S., Hunt, T., Merrell, R.C., and Fathman, C.G. (1986) Inhibition of rat mixed lymphocyte pancreatic islet cultures with anti-Ia immunotoxins. Transplantation, 42, 660–666.
John, D.T., (1982) Primary amebic meningoencephalitis and the biology of Naegleria fowleri. Ann. Res. Microb., 36, 101–123.
Seidel, J.S., Harmatz, P., Visvesvara, G.S., Cohen, A., Edwards, J., and Turner, J. (1982) Successful treatment of primary amoebic meningoencephalitis. New Engl. J. Med., 306, 346–348.
Martinez, A.J. (1982) Acanthamoebiasis and immunosuppression. J. Neuropath. Exp. Neurol., 41, 548–557.
Visvesvara, G.A., Mirra, S.S., Brandt, F.H., Moss, D. M., Mathews, H.V., and Martinez, A.J. (1983) Isolation of two strains of Acanthamoeba castellanii from human tissue and their pathogenicity and isoenzyme profiles. J. Clin. Microbiol., 18, 1405–1412.
Hanssens, M., de Jonckheere, J.F., and de Meunynck, C.H. (1985) Acanthamoeba keratitis — a clinicopathological case report. Inter. Opthal., 7, 203–213.
Hirst, L.W., Green, W.R., Merz, W., Kaufmann, C., Visvesvara, G.S., Jensen, A., and Howard, M. (1984) Management of acanthamoeba keratitis — a case report and review of literature. Ophthal., 91, 1105–1111.
Byers, T.J. (1979) Growth, reproduction and differentiation in acanthamoeba. Int. Rev. Cyto., 61, 283–337.
Howell, M.D., and Villemez, C.L. (1983) Toxicity of ricin, diphtheria toxin and alphamanitin for Acanthamoeba castellanii. J. Parasit., 70, 918–923.
Villemez, C.L., and Carlo, P.L. (1984) Preparation of an immunotoxin for Acanthamoeba castellanii. Biochem. Biophys. Res. Com., 125, 25–29.
Villemez, C.L., Russell, M.A., and Carlo, P.L. (1984) Mouse IgG1 heterogeneity: Variable binding of monoclonal IgG1 antibodies to protein A-sepharose. Mol. Immunol., 21, 993–998.
Villemez, C.L., Carlo, P.L., and Russell, M.A. (1985) Differentiation in Acanthamoeba castellanii is induced by specific monoclonal antibodies. J. Cell. Biochem., 29, 373–379.
Villemez, C.L., Russell, M.A., Barbieri, L., Stirpe, F., Irvin, J.D., and Robertus, J.D. (1986) Toxins for protozoan immunotoxins. UCLA Symp. Mol. Cell. Biol., 45, in press.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1988 Kluwer Academic Publishers
About this chapter
Cite this chapter
Bjorn, M.J., Villemez, C.L. (1988). Immunotoxins: Selection of cell-surface antigens and their corresponding monoclonal antibodies. In: Frankel, A.E. (eds) Immunotoxins. Cancer Treatment and Research, vol 37. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-1083-9_15
Download citation
DOI: https://doi.org/10.1007/978-1-4613-1083-9_15
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4612-8419-2
Online ISBN: 978-1-4613-1083-9
eBook Packages: Springer Book Archive